Best Diversified Pharmaceuticals Companies in New York, United States
The 32 best Diversified Pharmaceuticals companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Roivant Sciences.
Ranked: Best Diversified Pharmaceuticals companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 95 mo ago | 662 | Vivek Ramaswamy Founder | DrupalApple iCloud MailPHP+21 | — | — |
| 2 | ZymoGenetics Develop protein therapies for hematology, cancer, and inflammatory disorders | $100M | 220 mo ago | 65 | — | — | 1,926 patents Therapeutic antibodies targeting cytokines and immune checkpoints for inflammatory/autoimmune diseases | — |
| 3 | Stablix Developer of a drug discovery platform that focuses on targeted protein stabilization | $63M | 65 mo ago | 25 | Brian Bowman Co-Founder | WixSentryBootstrap+9 | 11 patents Small‑molecule Akt and PARP inhibitors plus USP deubiquitinase stabilizers for oncology | — |
| 4 | Inspirna Provider of drug research & development services for oncology treatment | $55M | 51 mo ago | 11 | — | — | 79 patents Cancer diagnostics and therapeutics targeting APOE, MERTK, and metabolic pathways | — |
| 5 | Fortress Biotech Developing novel immunotherapy agents for cancer and inflammatory diseases | $55M | 104 mo ago | 187 | Lindsay Rosenwald CEO | BootstrapApache HTTP ServerMatomo Analytics+15 | — | — |
| 6 | Seed Therapeutics R&D company focused on manufacturing of drugs for multiple therapeutic areas | $50M | 14 mo ago | 13 | Lan Huang Co-founder | WebflowGSAPSwiper+12 | — | — |
| 7 | Cyclo Therapeutics Developer of therapeutics for Niemann-Pick Disease Type C and Alzheimer’s Disease | $32M | 41 mo ago | 9 | N. Scott Fine Chairman & CEO | WordPressMySQLPHP+18 | — | — |
| 8 | Regeneron Pharmaceuticals Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | $30M | 194 mo ago | 13,450 | George Yancopoulos President | DrupalApple iCloud MailPHP+23 | — | — |
| 9 | Repair Biotechnologies Developer of protein & gene therapies for treatment of aging diseases | $20M | 11 mo ago | 6 | Bill Cherman Co-founder and Chairman | WordPressMySQLPHP+15 | 20 patents Metabolic engineering of cholesterol pathways for cardiovascular disease and cancer therapies | — |
| 10 | United Biomedical Discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious… | $9M | 350 mo ago | 42 | Nean Hu Co-Founder | — | 314 patents Peptide immunogen design for veterinary vaccines and human therapeutic peptide drugs | — |
| 11 | Innovimmune Innovating immunotherapies for cancer, autoimmune diseases, and chronic inflammation | $7M | 172 mo ago | — | Anderson Gaweco President & CEO | — | — | — |
| 12 | QBioMed Developer of chemotherapeutic agent for Hepatocellular carcinoma | $4M | 65 mo ago | 9 | Denis Corin Chief Executive Officer | — | — | — |
| 13 | Helocyte Developing immunotherapies for cancer and infectious diseases, particularly cytomegalovirus | $4M | 120 mo ago | 2 | — | — | — | — |
| 14 | Ember Therapeutics Therapeutics based on bone morphogenic protein - 7 | $3M | 178 mo ago | 1 | Joseph Hernandez Founder & CEO | — | — | — |
| 15 | Aspen Park Pharmaceuticals Developing oral small molecule drugs for men’s health and oncology | $1M | 127 mo ago | 2 | — | — | — | — |
| 16 | Biomedica Small molecule therapeutics for blood disorders | $300K | 138 mo ago | 4 | George Falus Founder | — | — | — |
| 17 | Serometrix Develops drug discovery platform for protein interactions | $228K | 172 mo ago | 2 | Michael Muehlemann CEO | — | 5 patents Peptide therapeutics inhibiting alpha-fetoprotein-driven tumor growth | — |
| 18 | Pfizer Provider of pharmaceutical products for multiple disease treatments | — | 40 mo ago | — | Sai Boddu Director | DrupalApple iCloud MailPHP+25 | — | — |
| 19 | Enzo Life science products and services for research, drug discovery, and manufacturing | — | 41 mo ago | 179 | Kara Cannon Chief Executive Officer | WordPress Block EditorCart FunctionalityWooCommerce+28 | — | — |
| 20 | Bristol-Myers Squibb Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | — | 86 mo ago | 153 | Giovanni Caforio Retired Chairman and CEO | WordPressApple iCloud MailMicrosoft 365+41 | 22,373 patents Immuno-oncology therapeutics, antibody checkpoint inhibitors, and novel small‑molecule drug scaffolds | — |
Top 12 Diversified Pharmaceuticals companies in New York
#1
Series A · Syracuse, New York · founded 2018 · 6 employees$19.8Mraised▾
Developer of protein & gene therapies for treatment of aging diseases
- Nov 2025Series A$5.3M
- Mar 2024Series A$6.2M
- Jun 2023Series A$8.6M
- Feb 2021Seed$200K
#2
Series A · New York City, New York · founded 2019 · 13 employees$50Mraised▾
R&D company focused on manufacturing of drugs for multiple therapeutic areas
- Aug 2025Series A$6M
- Aug 2024Series A$24M
- Nov 2020Series A$20M
#3
Public · New York City, New York · founded 2014 · 662 employees$1.3Braised▾
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimer's disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 2/3); RVT-103 and RVT-104 for Alzheimer's disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
- Nov 2018PE$200M
- Apr 2018Grant (prize money)$1.4M
- Aug 2017PE$1.1B
- Dec 2015Conventional Debt—
#4
Public · New York, New York · founded 1990 · 9 employees$32.1Mraised▾
Developer of therapeutics for Niemann-Pick Disease Type C and Alzheimer’s Disease. It focuses on developing medicines for patients and families living with these challenging diseases. The company leverages scientific innovation to advance its pipeline, which includes clinical trials and expanded access programs.
- Jun 2023Post IPO$5M
- Sep 2020Post IPO$2.8M
- Apr 2020Post IPO$2M
- Jun 2019Post IPO$7.4M
#5
Series D · New York City, New York · founded 2010 · 11 employees$55.1Mraised▾
Provider of drug research & development services for oncology treatment
- Jul 2022Series D$55.1M
- Feb 2021Series C$6M
- Oct 2018Series C$40M
- Jun 2016Series B$33M
#6
Series A · New York City, New York · founded 2021 · 25 employees$63Mraised▾
Developer of a drug discovery platform that focuses on targeted protein stabilization. The Restored platform generates heterobifunctional small-molecules that selectively recruit active deubiquitinases to target proteins to precisely remove ubiquitin and restore protein function. It is used for developing drugs to treat rare diseases, cancer, and immunological disorders.
#7
Public · New York City, New York · founded 2006 · 187 employees$54.9Mraised▾
Fortress Biotech is a developer of novel immunotherapy agents for cancer and inflammatory diseases. The company has developed CNDO-109, a compound that activates the natural killer ("NK") cells of the host immune system to seek and destroy cancer cells, for the treatment of cancer. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell structures. CNDO-109 has the potential to benefit patients with a wide variety of hematologic and solid cancers.
- Feb 2018Conventional Debt$6.5M
- Nov 2017Post IPO$25M
- Apr 2017Post IPO$3.3M
- Mar 2015Post IPO$10M
#8
Acquired · New York City, New York · founded 1981 · 65 employees$100Mraised▾
Develop protein therapies for hematology, cancer, and inflammatory disorders. Its developing pipeline had two phases two candidates PEG-Interferon lambda for hepatitis C virus infection, and IL-21 for metastatic melanoma besides a preclinical candidate anti-IL-31 monoclonal antibody (MAb) for atopic dermatitis.
- Jun 2008Venture Debt$100M
- Oct 2000PE—
#9
Public · Tarrytown, New York · founded 1988 · 13450 employees$29.7Mraised▾
Regeneron Pharmaceuticals is a developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others. It is developing antibody products include ARCALYST (rilonacept), an anti-inflammatory agent, EYLEA (aflibercept) Injection, also known as VEGF Trap-Eye, and Intravitreal Aflibercept injection. It has also developed PRALUENT (alirocumab) Injection that is a PCSK9 inhibitor. Its Phase 3 pipeline includes antibodies for the treatment of rheumatoid arthritis, topic dermatitis in adults, asthma, respiratory syncytial virus, chronic lower back pain, and others. Its Phase 2 pipeline drugs are for the treatment of Atopic dermatitis in children, nasal polyps, eosinophilic esophagitis, non-infectious uveitis, skeletal muscle disorders. In 2022, the company recorded annual revenues of $12.17B and a net profit of $4.33B.
- Aug 2010Grant (prize money)$14.9M
- Sep 2007Grant (prize money)$14.9M
#10
Public · New York City, New York · founded 2013 · 9 employees$4Mraised▾
QBiomed is a developer of a chemotherapeutic agent for Hepatocellular carcinoma. Its technology utilizes uttroside B and the compound's derivatives. It has developed UTTROSIDE-B that is a chemotherapeutic for liver and cancer. The product QBM- 001 acts as a radiopharmaceutical for metastatic cancer bone pain.
- May 2021Post IPO—
- Oct 2019Post IPO$500K
- Aug 2019Post IPO$500K
- Sep 2018Post IPO$4M
#11
Series A · Hauppauge, New York · founded 1983 · 42 employees$9Mraised▾
United Biomedical (UBI) is a is a privately held biopharmaceutical company for the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.Its product pipeline includes phase II of UB-311 for Alzheimer's and UB-421 for HIV; phase I of UBITh® immunotherapeutic for allergy ; pre-clinical development for HIV-RC vaccine. It is also using its UB-421 mAb product develop a series of lower risk biosimilar drugs with established clinical efficacies.
- Sep 1997Series A$9M
#12
Funding Raised · Brooklyn, New York · founded 2010$7.2Mraised▾
Innovating immunotherapies for cancer, autoimmune diseases, and chronic inflammation. This biotechnology company focuses on discovering and developing novel, oral small-molecule immunomodulatory drugs. Their strategic "Pipeline in a molecule" R&D approach aims to advance target-validated clinical candidates into parallel clinical development across multiple disease indications. They utilize structure-guided drug design, computational machine learning, and AI to develop new drugs by enabling intractable disease-associated proteins to become druggable therapeutic targets. The company seeks strategic partnerships to advance therapeutic discoveries and accelerate R&D through clinical development, approval, and commercialization. They are focused on delivering orally administered medicines that improve patient quality of life. Their pipeline includes LXR Agonist, MIF Inhibitor, ROR Gamma Inverse Agonist and ROR Gamma Agonist. They are developing first-in-class and best-in-class proprietary drugs.
- Jun 2012Grant (prize money)$600K
- Jul 2011Grant (prize money)$6.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.